Atopic dermatitis (AD) is a pruritic disease of unknown origin that usually starts in early infancy (an adult-onset variant is recognized).
Market Analysis and Insights: Global Atopic Dermatitis Drugs Market
Due to the COVID-19 pandemic, the global Atopic Dermatitis Drugs market size is estimated to be worth US$ 5694.9 million in 2022 and is forecast to a readjusted size of US$ 7514.8 million by 2028 with a CAGR of 4.7% during the review period. Fully considering the economic change by this health crisis, Injectable accounting for % of the Atopic Dermatitis Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
One of the major factors responsible for the growing risk of severe atopic dermatitis in infancy is related to food sensitization, which is commonly associated with food allergy. It has been observed that these allergies mainly result from the cow’s milk, chicken eggs, peanuts, wheat, soy, nuts, and fish.
Global Atopic Dermatitis Drugs Scope and Segment
Atopic Dermatitis Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Atopic Dermatitis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Injectable
Oral
Tropical
Segment by Application
Hospital
Clinic
By Company
LEO Pharma
Mylan
Valeant
Bayer HealthCare
Encore Dermatology
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E